Johnson & Johnson's stock experienced a surge following a better-than-expected earnings report and an upward revision of its full-year outlook. The positive news boosted investor sentiment, contributing to a rally in Johnson & Johnson's stock and providing a lift to the broader pharmaceutical sector.